Skip to main content
SpringerLink
Log in

Epidemiology of IGF-1 and Cancer

  • Chapter
  • First Online:
Insulin-like Growth Factors and Cancer

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

The incidence rates of cancer have been increasing steadily during the last 20 years in industrially developed parts of the world, notably Western Europe and North America (IARC 2008). The wide variation in cancer rates across the world as well as the observed increase in cancer risk among migrants moving from low-risk to ­high-risk countries convincingly suggest that environmental factors associated with a Western lifestyle may be major determinants of cancer risk. Western lifestyle is characterized by a diet high in total and saturated fat, refined sugars, and animal protein accompanied by physical inactivity. These lifestyle factors and overweight, which is most commonly related to Western diet and lifestyle, have been associated with insulin resistance and postprandial hyperinsulinemia, and many of them have been positively associated with different types of cancer in epidemiological studies. Both insulin and IGF-1 can enhance tumor development by stimulating cell proliferation and by inhibiting apoptosis. It has been hypothesized that variations in the insulin and insulin-like growth factor (IGF) pathways could account for the nutritional and lifestyle risk factors and the high cancer incidence in Western countries.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Albanes, D., S. J. Weinstein, et al. (2009). “Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer.” J Natl Cancer Inst 101(18): 1272–9.

    Google Scholar 

  • Allen, N. E., T. J. Key, et al. (2007). “Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.” Cancer Epidemiol.Biomarkers Prev 16(6): 1121–1127.

    Google Scholar 

  • Allen, N. E., A. W. Roddam, et al. (2005). “A prospective study of serum insulin-like growth ­factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk.” Br J Cancer 92(7): 1283–7.

    Google Scholar 

  • Baglietto, L., D. R. English, et al. (2007). “Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer.” Cancer Epidemiol Biomarkers Prev 16(4): 763–8.

    Google Scholar 

  • Baxter, R. C. (2001). “Signalling pathways involved in antiproliferative effects of IGFBP-3: a review.” Mol Pathol 54(3): 145–8.

    Google Scholar 

  • Becker, S. and R. Kaaks (2009). “Exogenous and endogenous hormones, mammographic density and breast cancer risk: can mammographic density be considered an intermediate marker of risk?” Recent Results Cancer Res 181: 135–57.

    Google Scholar 

  • Bohlke, K., D. W. Cramer, et al. (1998). “Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast.” Epidemiology 9(5): 570–3.

    Google Scholar 

  • Brabant, G. and H. Wallaschofski (2007). “Normal levels of serum IGF-I: determinants and validity of current reference ranges.” Pituitary 10(2): 129–33.

    Google Scholar 

  • Bruning, P. F., J. Van Doorn, et al. (1995). “Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer.” Int J Cancer 62(3): 266–70.

    Google Scholar 

  • Brunner, J. E., C. C. Johnson, et al. (1990). “Colon cancer and polyps in acromegaly: increased risk associated with family history of colon cancer.” Clin Endocrinol (Oxf) 32(1): 65–71.

    Google Scholar 

  • Cats, A., R. P. Dullaart, et al. (1996). “Increased epithelial cell proliferation in the colon of patients with acromegaly.” Cancer Res 56(3): 523–6.

    Google Scholar 

  • Chan, J. M., M. J. Stampfer, et al. (1998). “Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.” Science 279(5350): 563–6.

    Google Scholar 

  • Chan, J. M., M. J. Stampfer, et al. (2002). “Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.” J Natl Cancer Inst 94(14): 1099–106.

    Google Scholar 

  • Chen, C., S. K. Lewis, et al. (2005). “Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.” Cancer 103(1): 76–84.

    Google Scholar 

  • Cohen, P., D. M. Peehl, et al. (1993). “Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients.” J Clin Endocrinol Metab 76(4): 1031–5.

    Google Scholar 

  • Colao, A., R. Pivonello, et al. (2007). “The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients.” J Clin Endocrinol Metab 92(10): 3854–60.

    Google Scholar 

  • Dupont, J. and D. Le Roith (2001). “Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects.” Mol Pathol 54(3): 149–54.

    Google Scholar 

  • Eliassen, A. H., S. S. Tworoger, et al. (2007). “Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women.” Cancer Epidemiol Biomarkers Prev 16(1): 161–4.

    Google Scholar 

  • Engeland, A., S. Tretli, et al. (2005). “Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women.” Cancer Causes Control 16(8): 987–96.

    Google Scholar 

  • Finne, P., A. Auvinen, et al. (2000). “Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen.” J Clin Endocrinol Metab 85(8): 2744–7.

    Google Scholar 

  • Fletcher O., L. Gibson, et al. (2005). “Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review.” Cancer Epidemiol Biomarkers Prev 14(1):2–19.

    PubMed  CAS  Google Scholar 

  • Foltyn, W., B. Kos-Kudla, et al. (2008). “Is there any relation between hyperinsulinemia, insulin resistance and colorectal lesions in patients with acromegaly?” Neuro Endocrinol Lett 29(1): 107–12.

    Google Scholar 

  • Furstenberger, G. and H. J. Senn (2002). “Insulin-like growth factors and cancer.” Lancet Oncol 3(5): 298–302.

    Google Scholar 

  • Giovannucci, E. (2001). “Insulin, insulin-like growth factors and colon cancer: a review of the evidence.” J Nutr 131(11 Suppl): 3109S–20S.

    Google Scholar 

  • Giovannucci, E., Y. Liu, et al. (2007). “Risk factors for prostate cancer incidence and progression in the health professionals follow-up study.” Int J Cancer.

    Google Scholar 

  • Giovannucci, E., M. Pollak, et al. (2003). “Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men.” Cancer Epidemiol Biomarkers Prev 12(2): 84–9.

    Google Scholar 

  • Giovannucci, E., M. N. Pollak, et al. (2000). “A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women.” Cancer Epidemiol Biomarkers Prev 9(4): 345–9.

    Google Scholar 

  • Giovannucci, E., E. B. Rimm, et al. (2004). “Height, predictors of C-peptide and cancer risk in men.” Int J Epidemiol 33(1): 217–25.

    Google Scholar 

  • Glass, A. R., J. W. Kikendall, et al. (1994). “Serum concentrations of insulin-like growth factor 1 in colonic neoplasia.” Acta Oncol 33(1): 70–1.

    Google Scholar 

  • Gronbaek, H., A. Flyvbjerg, et al. (2004). “Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women.” Cancer Epidemiol Biomarkers Prev 13(11 Pt 1): 1759–64.

    Google Scholar 

  • Gunter, M. J., D. R. Hoover, et al. (2008). “Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women.” Cancer Res 68(1): 329–37.

    Google Scholar 

  • Gunter, M. J., D. R. Hoover, et al. (2009). “Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women.” J Natl Cancer Inst 101(1): 48–60.

    Google Scholar 

  • Hankinson, S. E., W. C. Willett, et al. (1998). “Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.” Lancet 351(9113): 1393–6.

    Google Scholar 

  • Harman, S. M., E. J. Metter, et al. (2000). “Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer.” J Clin Endocrinol Metab 85(11): 4258–65.

    Google Scholar 

  • Harrela, M., H. Koistinen, et al. (1996). “Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3.” J Clin Invest 98(11): 2612–5.

    Google Scholar 

  • Holmes, M. D., M. N. Pollak, et al. (2002). “Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations.” Cancer Epidemiol Biomarkers Prev 11(9): 852–61.

    Google Scholar 

  • Hsing, A. W., Y. T. Gao, et al. (2003). “Insulin resistance and prostate cancer risk.” J Natl Cancer Inst 95(1): 67–71.

    Google Scholar 

  • Hsing, A. W., L. C. Sakoda, et al. (2007). “Obesity, metabolic syndrome, and prostate cancer.” Am J Clin Nutr 86(3): s843-57.

    Google Scholar 

  • IARC (2008). World Cancer Report 2008. Lyon, World Health Organization, International Agency for Research on Cancer.

    Google Scholar 

  • Jenkins, P. J. (2004). “Acromegaly and cancer.” Horm Res 62 Suppl 1: 108–15.

    Google Scholar 

  • Jenkins, P. J., P. D. Fairclough, et al. (1997). “Acromegaly, colonic polyps and carcinoma.” Clin Endocrinol (Oxf) 47(1): 17–22.

    Google Scholar 

  • Jenkins, P. J., V. Frajese, et al. (2000). “Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly.” J Clin Endocrinol Metab 85(9): 3218–21.

    Google Scholar 

  • Johansson, M., J. D. McKay, et al. (2009). “Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival.” Prostate 69(12): 1281–91.

    Google Scholar 

  • Juul, A., P. Bang, et al. (1994). “Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index.” J Clin Endocrinol Metab 78(3): 744–52.

    Google Scholar 

  • Kaaks, R. (2004). “Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence.” Novartis Found Symp 262: 247–60; discussion 260–68.

    Google Scholar 

  • Kaaks, R. and A. Lukanova (2001). “Energy balance and cancer: the role of insulin and insulin-like growth factor-I.” Proc Nutr Soc 60(1): 91–106.

    Google Scholar 

  • Kaaks, R., E. Lundin, et al. (2002). “Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden.” Cancer Causes Control 13(4): 307–16.

    Google Scholar 

  • Kaaks, R., P. Toniolo, et al. (2000). “Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women.” J Natl Cancer Inst 92(19): 1592–600.

    Google Scholar 

  • Kanety, H., Y. Madjar, et al. (1993). “Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen.” J Clin Endocrinol Metab 77(1): 229–33.

    Google Scholar 

  • Keinan-Boker, L., H. B. Bueno De Mesquita, et al. (2003). “Circulating levels of insulin-like growth factor I, its binding proteins −1,-2, -3, C-peptide and risk of postmenopausal breast cancer.” Int J Cancer 106(1): 90–5.

    Google Scholar 

  • Key, T. J., P. N. Appleby, et al. (2010) “Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies.” Lancet Oncol 11(6): 530–42.

    Google Scholar 

  • Krajcik, R. A., N. D. Borofsky, et al. (2002). “Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.” Cancer Epidemiol Biomarkers Prev 11(12): 1566–73.

    Google Scholar 

  • Lacey, J. V., Jr., A. W. Hsing, et al. (2001). “Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study.” Cancer Epidemiol Biomarkers Prev 10(10): 1101–2.

    Google Scholar 

  • Larsson, S. C., N. Orsini, et al. (2005). “Diabetes mellitus and risk of colorectal cancer: a meta-analysis.” J Natl Cancer Inst 97(22): 1679–87.

    Google Scholar 

  • Ma, J., E. Giovannucci, et al. (2004). “A prospective study of plasma C-peptide and colorectal cancer risk in men.” J Natl Cancer Inst 96(7): 546–53.

    Google Scholar 

  • Ma, J., H. Li, et al. (2008). “Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis.” Lancet Oncol 9(11): 1039–47.

    Google Scholar 

  • Ma, J., M. N. Pollak, et al. (1999). “Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.” J Natl Cancer Inst 91(7): 620–5.

    Google Scholar 

  • Manousos, O., J. Souglakos, et al. (1999). “IGF-I and IGF-II in relation to colorectal cancer.” Int J Cancer 83(1): 15–7.

    Google Scholar 

  • Mantzoros, C. S., A. Tzonou, et al. (1997). “Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.” Br J Cancer 76(9): 1115–8.

    Google Scholar 

  • Max, J. B., P. J. Limburg, et al. (2008). “IGF-I, IGFBP-3, and IGF-I/IGFBP-3 ratio: no association with incident colorectal cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.” Cancer Epidemiol Biomarkers Prev 17(7): 1832–4.

    Google Scholar 

  • McMenamin, M. E., P. Soung, et al. (1999). “Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.” Cancer Res 59(17): 4291–6.

    Google Scholar 

  • Meyer, F., P. Galan, et al. (2005). “A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial.” Cancer Epidemiol Biomarkers Prev 14(9): 2269–72.

    Google Scholar 

  • Monti, S., L. Proietti-Pannunzi, et al. (2007). “The IGF axis in prostate cancer.” Curr Pharm Des 13(7): 719–27.

    Google Scholar 

  • Morris, J. K., L. M. George, et al. (2006). “Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies.” Br J Cancer 95(1): 112–7.

    Google Scholar 

  • Muti, P., T. Quattrin, et al. (2002). “Fasting glucose is a risk factor for breast cancer: a prospective study.” Cancer Epidemiol Biomarkers Prev 11(11): 1361–8.

    Google Scholar 

  • Nimptsch, K., E. A. Platz, et al. (2010). “Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993–2004.” Int J Cancer.

    Google Scholar 

  • Nomura, A. M., G. N. Stemmermann, et al. (2003). “Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men.” Am J Epidemiol 158(5): 424–31.

    Google Scholar 

  • Otani, T., M. Iwasaki, et al. (2005). “Body mass index, body height, and subsequent risk of colorectal cancer in middle-aged and elderly Japanese men and women: Japan public health center-based prospective study.” Cancer Causes Control 16(7): 839–50.

    Google Scholar 

  • Otani, T., M. Iwasaki, et al. (2007). “Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study.” Int J Cancer 120(9): 2007–12.

    Google Scholar 

  • Palmqvist, R., G. Hallmans, et al. (2002). “Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden.” Gut 50(5): 642–6.

    Google Scholar 

  • Palmqvist, R., P. Stattin, et al. (2003). “Plasma insulin, IGF-binding proteins-1 and −2 and risk of colorectal cancer: a prospective study in northern Sweden.” Int J Cancer 107(1): 89–93.

    Google Scholar 

  • Peyrat, J. P., J. Bonneterre, et al. (1993). “Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer.” Eur J Cancer 29A(4): 492–7.

    Google Scholar 

  • Pisani, P. (2008). “Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies.” Arch Physiol Biochem 114(1): 63–70.

    Google Scholar 

  • Pischon, T., P. H. Lahmann, et al. (2006). “Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC).” J Natl Cancer Inst 98(13): 920–31.

    Google Scholar 

  • Platz E. A., M. N. Pollak, et al. (1999). “Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men.” Cancer Epidemiol Biomarkers Prev 8(12):1107–10.

    PubMed  CAS  Google Scholar 

  • Platz, E. A., M. N. Pollak, et al. (2005). “Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.” Cancer Causes Control 16(3): 255–62.

    Google Scholar 

  • Pollak, M. (2008). “Insulin and insulin-like growth factor signalling in neoplasia.” Nat Rev Cancer 8(12): 915–28.

    Google Scholar 

  • Pollak, M., W. Beamer, et al. (1998). “Insulin-like growth factors and prostate cancer.” Cancer Metastasis Rev 17(4): 383–90.

    Google Scholar 

  • Probst-Hensch, N. M., J. M. Yuan, et al. (2001). “IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai.” Br J Cancer 85(11): 1695–9.

    Google Scholar 

  • Renehan A. G., M. Zwahlen, et al. (2004). “Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis.” Lancet 363(9418): 1346–53.

    Article  PubMed  CAS  Google Scholar 

  • Renehan, A. G., M. Harvie, et al. (2006). “Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on.” Endocr Relat Cancer 13(2): 273–8.

    Google Scholar 

  • Rinaldi, S., R. Cleveland, et al. (2010). “Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies.” Int J Cancer 126(7): 1702–15.

    Google Scholar 

  • Rinaldi, S., R. Kaaks, et al. (2005). “Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays.” Cancer Epidemiol Biomarkers Prev 14(1): 48–52.

    Google Scholar 

  • Rinaldi, S., P. H. Peeters, et al. (2006). “IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC).” Endocr Relat Cancer 13(2): 593–605.

    Google Scholar 

  • Roddam, A. W., N. E. Allen, et al. (2008). “Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies.” Ann Intern Med 149(7): 461–71, W83-8.

    Google Scholar 

  • Rollison, D. E., C. J. Newschaffer, et al. (2006). “Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer.” Int J Cancer 118(5): 1279–84.

    Google Scholar 

  • Ron, E., G. Gridley, et al. (1991). “Acromegaly and gastrointestinal cancer.” Cancer 68(8): 1673–7.

    Google Scholar 

  • Rowlands, M. A., D. Gunnell, et al. (2009). “Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis.” Int J Cancer 124(10): 2416–29.

    Google Scholar 

  • Savage, C. J., H. Lilja, et al. (2010) “Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.” Cancer Epidemiol Biomarkers Prev 19(5): 1201–7.

    Google Scholar 

  • Schairer, C., McCarty, C.A., Isaacs, C., Sue, L.Y., Pollak, M.N., Berg, C.D., Ziegler, R.G. (2010). “Circulating insulin-like growth factor (IGF)-1 and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) Cohort.” Hormones and Cancer(1): 100–111.

    Google Scholar 

  • Schernhammer, E. S., J. M. Holly, et al. (2006). “Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.” Endocr Relat Cancer 13(2): 583–92.

    Google Scholar 

  • Schernhammer, E. S., J. M. Holly, et al. (2005). “Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.” Cancer Epidemiol Biomarkers Prev 14(3): 699–704.

    Google Scholar 

  • Schumacher, F. R., I. Cheng, et al. (2010). “A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians.” Hum Mol Genet.

    Google Scholar 

  • Severi, G., H. A. Morris, et al. (2006). “Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.” Cancer Epidemiol Biomarkers Prev 15(6): 1137–41.

    Google Scholar 

  • Shi R., H. Yu, et al. (2004). “IGF-I and breast cancer: a meta-analysis.” Int J Cancer 111(3):418–23.

    Article  PubMed  CAS  Google Scholar 

  • Stattin, P., A. Bylund, et al. (2000). “Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.” J Natl Cancer Inst 92(23): 1910–7.

    Google Scholar 

  • Stattin, P., S. Rinaldi, et al. (2004). “High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.” J Clin Oncol 22(15): 3104–12.

    Google Scholar 

  • Stocks, T., A. Lukanova, et al. (2007). “Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden.” Int J Cancer 120(12): 2678–86.

    Google Scholar 

  • Sugumar A., Y. C. Liu, et al. (2004). “ Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature.” Int J Cancer 111(2): 293–7.

    Article  PubMed  CAS  Google Scholar 

  • Toniolo, P., P. F. Bruning, et al. (2000). “Serum insulin-like growth factor-I and breast cancer.” Int J Cancer 88(5): 828–32.

    Google Scholar 

  • Vatten, L. J., J. M. Holly, et al. (2008). “Nested case-control study of the association of circulating levels of serum insulin-like growth factor I and insulin-like growth factor binding protein 3 with breast cancer in young women in Norway.” Cancer Epidemiol Biomarkers Prev 17(8): 2097–100.

    Google Scholar 

  • Verheus, M., P. H. Peeters, et al. (2006). “Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC).” Int J Cancer 119(3): 659–67.

    Google Scholar 

  • Wei, E. K., E. Giovannucci, et al. (2004). “Comparison of risk factors for colon and rectal cancer.” Int J Cancer 108(3): 433–42.

    Google Scholar 

  • Wei, E. K., J. Ma, et al. (2005). “A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women.” Cancer Epidemiol Biomarkers Prev 14(4): 850–5.

    Google Scholar 

  • Weiss, J. M., W. Y. Huang, et al. (2007). “IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.” Int J Cancer 121(10): 2267–73.

    Google Scholar 

  • Woodson, K., J. A. Tangrea, et al. (2003). “Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.” Cancer Res 63(14): 3991–4.

    Google Scholar 

  • World Cancer Research Fund/American Institute for Cancer, R. (2007). Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective.. Washington DC AICR.

    Google Scholar 

  • Zuccolo, L., R. Harris, et al. (2008). “Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis.” Cancer Epidemiol Biomarkers Prev 17(9): 2325–36.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nutrition, Harvard School of Public Health, Boston, MA, USA

    Katharina Nimptsch & Edward Giovannucci

  2. Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA

    Edward Giovannucci

Authors
  1. Katharina Nimptsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward Giovannucci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward Giovannucci .

Editor information

Editors and Affiliations

  1. , Department of Medicine, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, NEW YORK, 10029, USA

    Derek LeRoith

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Nimptsch, K., Giovannucci, E. (2012). Epidemiology of IGF-1 and Cancer. In: LeRoith, D. (eds) Insulin-like Growth Factors and Cancer. Cancer Drug Discovery and Development. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-0598-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-0598-6_1

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-0597-9

  • Online ISBN: 978-1-4614-0598-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation